Despite Aubagio lift, Sanofi Q1 sales dip

Share this article:

While M&A fervor continues to sweep much of big pharma, Sanofi CEO Christopher Viehbacher says his company is staying above the fray, according to Reuters.

During the company's announcement of Q1 2014 earnings, Viehbacher said the company will continue to look for assets from smaller firms, rather than merge with a large drugmaker.

Overall, the company saw sales of $10.8 billion, a decrease of 2.7% from 2013's first quarter. Jefferies analyst Jeffrey Holford stated in an investor note this morning that “group sales were 2% light. Pharma [sales were] in line, whilst Animal Health missed by 4% and vaccines missed by 9%,” vs. consensus estimates.

The French drugmaker's blockbuster insulin product Lantus was also “4% light” compared to consensus estimates, according to Holford, generating $1.9 billion in overall sales for the quarter.

Sanofi's consumer health division reported $1.2 billion in sales, growing by 18%. A highlight was allergy drug Nasacort's OTC launch in February. Sanofi's Genzyme unit also had a strong quarter, with sales of $566 million, driven by MS pill Aubagio's revenue of $107 million, compared to $27 million last year.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Payment database confounds doctors

ProPublica reports that doctors are struggling with a time-intensive registration process and are getting an error message that CMS says is not an error message.

Gilead's idelalisib hat trick

The FDA greenlighted the drug for three cancers.

Shire expands rare disease reach

A $225-million deal with US biotech ArmaGen gives Shire worldwide commercialization rights to an experimental enzyme replacement therapy.